ChosenMed successfully closed a Series C2 financing, raising several hundred million RMB from YiJing Capital, with participation from Linzhuo Industry Fund and other leading institutions.

CEC Capital Group served as the exclusive financial advisor in this transaction.

The proceeds from this financing will primarily be used for the development of ChosenMed's proprietary tumor early screening product pipeline, the construction of research and development facilities, and optimization of their drug CRO service platform.